{"id":796897,"date":"2024-12-24T07:03:10","date_gmt":"2024-12-24T12:03:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/"},"modified":"2024-12-24T07:03:10","modified_gmt":"2024-12-24T12:03:10","slug":"enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/","title":{"rendered":"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit<\/b><\/p>\n<p>WATERTOWN, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54170813&amp;newsitemid=20241224565771&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=c412227958438d701e3e355f86717b04\">Enanta Pharmaceuticals, Inc<\/a>. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (\u201cthe Court\u201d) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta\u2019s patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (\u201cthe \u2019953 Patent\u201d) in the manufacture, use and sale of Pfizer\u2019s COVID-19 antiviral, Paxlovid\u2122 (nirmatrelvir tablets; ritonavir tablets).<\/p>\n<p>\nThe Court issued a summary judgment decision granting Pfizer\u2019s motion that the \u2018953 Patent is invalid. In its decision, the Court also denied Enanta\u2019s partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit.<\/p>\n<p>\n&#8220;The U.S. patent system and its protection of important innovations have enabled the robust development of new medicines and spurred growth in the biotechnology industry. We are proud of the impact our strong history of drug discovery work with protease inhibitors has had on antiviral treatments and the thousands of patients that have been treated with therapies using our patented inventions,\u201d said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals, Inc. \u201cWe are disappointed with the Court\u2019s ruling. We believe strongly in the merits of our case, and, through the appeal process, we will continue to defend our inventions from unlawful infringement.\u201d<\/p>\n<p>\nEnanta maintains its commitment to avoid attempting to impede the production, sale or distribution of Paxlovid.<\/p>\n<p><b>About Enanta Pharmaceuticals, Inc.<\/b><\/p>\n<p>\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta\u2019s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.<\/p>\n<p>\nGlecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae (U.S.) and MAVIRET\u00ae (ex-U.S.) (glecaprevir\/pibrentasvir). A portion of Enanta\u2019s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta\u2019s operations. Please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com&amp;esheet=54170813&amp;newsitemid=20241224565771&amp;lan=en-US&amp;anchor=www.enanta.com&amp;index=2&amp;md5=15a8a124073d0ea6d788a143ea5a1318\">www.enanta.com<\/a> for more information.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements, including statements with respect to Enanta\u2019s suit against Pfizer, Inc. in the United States District Court for the District of Massachusetts seeking damages for patent infringement. Statements that are not historical facts are based on management\u2019s current expectations, estimates, forecasts and projections about Enanta\u2019s business and the industry in which it operates and management\u2019s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta is competing to develop intellectual property in areas of small-molecule drug development that are highly competitive; issued patents, including the patent at issue in the Pfizer litigation, could be found invalid or unenforceable if challenged in court and could be costly to defend and be a distraction for Enanta\u2019s senior management and scientific personnel; intellectual property litigation may lead to unfavorable publicity that harms Enanta\u2019s reputation and causes the market price of its common stock to decline; and other risk factors described or referred to in \u201cRisk Factors\u201d in Enanta\u2019s Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20241224565771\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20241224565771\/en\/<\/a><\/span><\/p>\n<p>\nMedia and Investors:<br \/>\n<br \/>Jennifer Viera<br \/>\n<br \/>617-744-3848<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jviera@enanta.com\">jviera@enanta.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> COVID-19 Legal Infectious Diseases Patent Law Clinical Trials Professional Services Biotechnology Health Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20241224565771\/en\/1475183\/3\/Enanta_RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (\u201cthe Court\u201d) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta\u2019s patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (\u201cthe \u2019953 Patent\u201d) in the manufacture, use and sale of Pfizer\u2019s COVID-19 antiviral, Paxlovid\u2122 (nirmatrelvir tablets; ritonavir tablets). The Court issued a summary judgment decision granting Pfizer\u2019s motion that the \u2018953 Patent is invalid. In its decision, the Court also denied Enanta\u2019s partial motion for summary &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-796897","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (\u201cthe Court\u201d) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta\u2019s patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (\u201cthe \u2019953 Patent\u201d) in the manufacture, use and sale of Pfizer\u2019s COVID-19 antiviral, Paxlovid\u2122 (nirmatrelvir tablets; ritonavir tablets). The Court issued a summary judgment decision granting Pfizer\u2019s motion that the \u2018953 Patent is invalid. In its decision, the Court also denied Enanta\u2019s partial motion for summary &hellip; Continue reading &quot;Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-24T12:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit\",\"datePublished\":\"2024-12-24T12:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/\"},\"wordCount\":763,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/\",\"name\":\"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2024-12-24T12:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit - Market Newsdesk","og_description":"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (\u201cthe Court\u201d) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta\u2019s patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (\u201cthe \u2019953 Patent\u201d) in the manufacture, use and sale of Pfizer\u2019s COVID-19 antiviral, Paxlovid\u2122 (nirmatrelvir tablets; ritonavir tablets). The Court issued a summary judgment decision granting Pfizer\u2019s motion that the \u2018953 Patent is invalid. In its decision, the Court also denied Enanta\u2019s partial motion for summary &hellip; Continue reading \"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-24T12:03:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit","datePublished":"2024-12-24T12:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/"},"wordCount":763,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/","name":"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2024-12-24T12:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241224565771r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-appeal-ruling-related-to-953-patent-infringement-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/796897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=796897"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/796897\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=796897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=796897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=796897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}